Crescent Biopharma shareholders re-elect directors, ratify auditor, approve say-on-pay

CRESCENT BIOPHARMA, INC.

Jonathan Violin, Ph.D. elected Class II director with 2,890,000 votes (all from preferred shares).
Susan Moran, M.D., MSCE elected Class II director with 21,401,136 votes FOR; 136,056 WITHHELD.
Ratification of PricewaterhouseCoopers as auditor approved with 21,049,101 FOR (1,452 against).
Non-binding say-on-pay approved: 18,346,099 FOR; 300,217 AGAINST. Board set future vote every 1 year.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CRESCENT BIOPHARMA, INC. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-02 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-02

Exact text from the filing

Proposal No. 2 - Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 21,049,101 1,452 154 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CRESCENT BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers at the 2026-06-02 meeting.

Proposal: say on pay frequency
Outcome: passed
Meeting: 2026-06-02

Exact text from the filing

Proposal No. 4 - Approval, on a non-binding advisory basis, of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers. 1 YEAR 2 YEARS 3 YEARS Votes ABSTAINED Broker Non-Votes 18,644,881 903 887 521 2,403,515

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CRESCENT BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-02 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-02

Exact text from the filing

Proposal No. 3 - Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 18,346,099 300,217 876 2,403,515

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CRESCENT BIOPHARMA, INC. shareholders approved Election of two Class II directors to serve until the Company's 2029 Annual General Meeting of Shareholders at the 2026-06-02 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-02

Exact text from the filing

Proposal No. 1A and Proposal No. 1B - Election of two Class II directors to serve until the Company’s 2029 Annual General Meeting of Shareholders and until their respective successors have been duly elected and qualified or until their earlier death, resignation, disqualification or removal. Votes FOR Votes WITHHELD Broker Non-Votes Jonathan Violin, Ph.D. (Proposal No. 1A) 2,890,000 0 0 Susan Moran, M.D., MSCE (Proposal No. 1B) 21,401,136 136,056 2,403,515

View on SEC.gov

1591 shareholder votes filed in the last 30 days. Browse all shareholder votes →

CRESCENT BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001628280-26-040051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.